Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsSilvia Santamarina-Fojo, Jeffrey M. Hoeg, H. Bryan Brewer, Jr.
Life of this patent
Estimating the term…
Abstract
This invention provides methods for treating atherosclerosis in a mammalian subject by increasing the activity of LCAT in the serum of the subject to a level effective to decrease the accumulation of cholesterol in the subject. Pharmaceutical dosage forms containing LCAT also are provided.
Claims8
A method for decreasing accumulation of cholesterol in arteries in a human subject not suffering from a lecithin:cholesterol acyltransferase (“LCAT”) deficiency syndrome comprising administering systemically to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of LCAT polypeptide effective to decrease the accumulation of cholesterol in arteries of the subject.
Dependencies are inferred from the claim text.